WEKO3
アイテム
Targeting the Extracellular Signal-Regulated Kinase Pathway in Cancer Therapy
http://hdl.handle.net/10069/27064
http://hdl.handle.net/10069/270649ce19b5c-8448-44c8-98ad-dfc5ecf9d369
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
BPB34_1781.pdf (753.5 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2012-01-10 | |||||||||||
| タイトル | ||||||||||||
| タイトル | Targeting the Extracellular Signal-Regulated Kinase Pathway in Cancer Therapy | |||||||||||
| 言語 | ||||||||||||
| 言語 | eng | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | Anticancer drug | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | Combination therapy | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | ERK pathway | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | MEK inhibitor | |||||||||||
| キーワード | ||||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | Molecular targeted therapy | |||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||
| 資源タイプ | journal article | |||||||||||
| 著者 |
Kohno, Michiaki
× Kohno, Michiaki
× Tanimura, Susumu
× Ozaki, Kei-ichi
|
|||||||||||
| 抄録 | ||||||||||||
| 内容記述タイプ | Abstract | |||||||||||
| 内容記述 | The extracellular signal-regulated kinase (ERK) pathway is a major determinant in the control of diverse cellular processes such as proliferation, survival, and motility. This pathway is often upregulated in human cancers and as such represents an attractive target for mechanism-based approaches to cancer treatment. However, specific blockade of the ERK pathway alone induces mostly cytostatic rather than proapoptotic effects, resulting in limited therapeutic efficacy. Blockade of the constitutively activated ERK pathway by an ERK kinase (MEK) inhibitor sensitizes tumor cells to apoptotic cell death induced by several cytotoxic anticancer agents including microtubule-destabilizing agents and histone deacetylase inhibitors, not only in vitro but also in tumor zenografts in vivo. Thus, low concentrations of these anticancer drugs that by themselves show little cytotoxicity effectively kill tumor cells in which the ERK pathway is constitutively activated when co-administrated with a MEK inhibitor. The combination of a cytostatic signaling pathway inhibitor (MEK inhibitors) and conventional anticancer drugs (microtubule-destabilizing agents or histone deacetylase inhibitors) provides an excellent basis for the development of safer anticancer chemotherapies with enhanced efficacy through lowering the required dose of the latter cytotoxic drugs. | |||||||||||
| 書誌情報 |
Biological and Pharmaceutical Bulletin 巻 34, 号 12, p. 1781-1784, 発行日 2011-12 |
|||||||||||
| 出版者 | ||||||||||||
| 出版者 | Pharmaceutical Society of Japan | |||||||||||
| 出版者別言語 | ||||||||||||
| 日本薬学会 | ||||||||||||
| ISSN | ||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||
| 収録物識別子 | 09186158 | |||||||||||
| EISSN | ||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||
| 収録物識別子 | 13475215 | |||||||||||
| 書誌レコードID | ||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||
| 収録物識別子 | AA10885497 | |||||||||||
| 権利 | ||||||||||||
| 権利情報 | © 2011 Pharmaceutical Society of Japan. | |||||||||||
| 著者版フラグ | ||||||||||||
| 出版タイプ | VoR | |||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||
| 引用 | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | Biological and Pharmaceutical Bulletin, 34(12), pp.1781-1784; 2011 | |||||||||||
